Intravenous Midazolam Versus Diazepam for Management of Non-Convulsive Status Epilepticus with Unknown Time of Symptom Onset: a Randomized Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027967

Enrollment

Unknown

Registered

2019-12-07

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status Epilepticus

Interventions

Midazolam Group:intravenous midazolam

Diazapam Group:intravenous diazapam

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >18 years. 2. Glasgow scale = 1h. 4. Ictal discharge was detected by electroencephalogram.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with epileptic encephalitis prior to the onset of non-convulsive status epilepticus. 2. Convulsive status epilepticus. 3. Using other intravenous anti-epileptic drugs. 4. Serious hepatic or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
The recurrence rate of NCSE within 14 days;The change from baseline in mean daily Glasgow score during the days 1-14;	—

Secondary

Measure	Time frame
The ratio of patients with Glasgow score > 14 within 14 days;The mean of mRS score after 30 days;The mean length of intensive care unit admission;The mean length of hospital admission;The remission rate of NCSE within 10 minutes;	—

Countries

China

Contacts

Public ContactWu Yuan

The First Affiliated Hospital to Guangxi Medical University

wuyuan90@126.com+86 13607713316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026